文献速递糖尿病肥胖与代谢综合征

胰高血糖素样肽1受体激动剂在亚洲与白种人群中心血管结局疗效比较:针对伴或不伴2型糖尿病和/或超重或肥胖人群随机试验的系统综述与Meta分析

Comparative Efficacy of Glucagon-Like Peptide 1 Receptor Agonists for Cardiovascular Outcomes in Asian Versus White Populations: Systematic Review and Meta-analysis of Randomized Trials of Populations With or Without Type 2 Diabetes and/or Overweight or Obesity.
PubMed 文献 · Diabetes Care · 2025-01-01

该系统综述与Meta分析纳入8项安慰剂对照心血管结局随机试验,比较胰高血糖素样肽1受体激动剂(GLP-1RA)在亚洲与白种人群中的心血管疗效。亚洲人群主要不良心血管事件(MACE)的HR为0.69(95%CI 0.58,0.83),白种人群为0.85(95%CI 0.79,0.91),交互作用P=0.045;亚洲人群MACE绝对风险降低2.9%(95%CI 1.5,4.2),白种人群降低1.4%(95%CI 0.9,1.9)。作者认为GLP-1RA在亚洲人群中可能带来更大的MACE降低。

要点

  • 亚洲人群GLP-1RA相关MACE的HR为0.69(95%CI 0.58,0.83),白种人群为0.85(95%CI 0.79,0.91)。
  • 亚洲人群MACE绝对风险降低2.9%(95%CI 1.5,4.2),白种人群降低1.4%(95%CI 0.9,1.9)。
  • 作者认为GLP-1RA在亚洲人群中可能带来更大的MACE降低。

核心结论

  • 作者认为GLP-1RA在亚洲人群中可能比白种人群带来更大的MACE降低。

研究设计与样本

  • 系统综述与Meta分析,检索PubMed和ClinicalTrials.gov(2015年1月1日至2024年11月1日)。
  • 纳入8项GLP-1RA安慰剂对照心血管结局随机试验,包括5,909名亚洲个体和55,855名白种个体。
  • 采用随机效应Meta分析,按PRISMA指南进行,并用RoB 2评估偏倚风险。

主要发现

  • GLP-1RA相关MACE的HR在亚洲人群为0.69(95%CI 0.58,0.83),在白种人群为0.85(95%CI 0.79,0.91),交互作用P=0.045。
  • MACE绝对风险降低在亚洲人群为2.9%(95%CI 1.5,4.2),在白种人群为1.4%(95%CI 0.9,1.9)。

局限性

  • 缺乏个体患者水平数据,无法对亚洲组进行详细亚分类。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cardiovascular outcome trials (CVOTs) suggest glucagon-like peptide 1 receptor agonists (GLP-1RAs) provide greater cardiovascular (CV) benefits in Asian compared with White individuals. PURPOSE: Compare CV efficacy of GLP-1RAs between Asian and White individuals. DATA SOURCES: Systematic review of PubMed and ClinicalTrials.gov (1 January 2015 to 1 November 2024). STUDY SELECTION: Randomized placebo-controlled CVOTs of GLP-1RAs. Risk of bias was assessed (RoB 2). DATA EXTRACTION: Ethnicity-specific hazard ratios (HRs) for major adverse cardiovascular events (MACE). DATA SYNTHESIS: Random-effects meta-analyses per Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines included eight trials (5,909 Asian individuals, 55,855 White individuals). GLP-1RA-associated MACE HR was 0.69 (95% CI 0.58, 0.83) in Asian people and 0.85 (95% CI 0.79, 0.91) in White people (Pinteraction = 0.045). Absolute MACE risk reduction was 2.9% (95% CI 1.5, 4.2) in Asian people versus 1.4% (0.9, 1.9) in White people. LIMITATIONS: Lack of individual patient-level data precluded detailed subclassification of the Asian group. CONCLUSIONS: GLP-1RAs may offer greater MACE reductions in Asian compared with White individuals.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Lee MMY, Ghouri N, Misra A, et al. Comparative Efficacy of Glucagon-Like Peptide 1 Receptor Agonists for Cardiovascular Outcomes in Asian Versus White Populations: Systematic Review and Meta-analysis of Randomized Trials of Populations With or Without Type 2 Diabetes and/or Overweight or Obesity. Diabetes Care. 2025. PMID: 39977628. doi:10.2337/dc24-1533

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。